5 unknown, 4 completed, 3 not yet recruiting, 3 terminated. 9 Phase 2, 7 Phase 1, 1 Not applicable.
Follow Indolent Lymphoma: new trials by email Literature Review of Indolent Lymphoma trials Research Report on Indolent Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma Lisaftoclax - Indolent Lymphoma, WM | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 75 | 2026-07-10 | 2026-07-29 |
| Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Pomalidomide - Indolent Lymphoma, Follicular Lymphoma | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-05-01 | 2026-05-27 | |
| Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma Induction therapy of GP(Pomalidomide+Obinutuzumab）, maintenance therapy of GP(Pomalidomide+Obinutuzumab） - Indolent Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 53 | 2026-03-20 | 2026-03-02 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia Pacritinib - Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Shayna Sarosiek, MD | 30 | 2025-11-21 | 2025-12-05 |
| Low-dose Radiotherapy in iNHL Low-dose radiotherapy - Indolent Lymphoma, Low-dose Radiotherapy | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 73 | 2022-05-01 | 2022-09-16 |
| PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies PSB202 - Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Unknown | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 110 | 2021-11-15 | 2022-03-28 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers NKX019 - Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Nkarta, Inc. | 150 | 2021-08-20 | 2026-04-20 |
| Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period vegan diet and lifestyle changes - Indolent Lymphoma | Not applicable | Unknown | Tel-Aviv Sourasky Medical Center | 40 | 2021-07-05 | 2023-04-21 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma Copanlisib, Nivolumab, Rituximab - Indolent Lymphoma | Phase 1 | Terminated | University of Michigan Rogel Cancer Center | 6 | 2020-06-15 | 2024-09-27 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies STRO-001 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Completed | Sutro Biopharma, Inc. | 70 | 2018-02-22 | 2024-06-11 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Zydelig - Non Hodgkin Lymphoma, Follicular Lymphoma | Phase 2 | Completed | University of Maryland, Baltimore | 17 | 2017-10-23 | 2025-06-27 |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Ledipasvir and sofosbuvir - Indolent Lymphoma | Phase 2 | Unknown | National Taiwan University Hospital | 21 | 2017-09-01 | 2017-08-25 |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies SB1518 - Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | S*BIO | 28 | 2010-12-01 | 2012-04-20 |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma rituximab, bortezomib, cladribine - Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | University of Arizona | 24 | 2009-07-07 | 2019-12-30 |
| 11C-Acetate PET/CT Non-FDG-Avid Tumors Soft Tissue Sarcomas, Thyroid Cancer | Unknown | Tel-Aviv Sourasky Medical Center | 100 | 2008-05-01 | 2008-06-02 | |
| Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma Therapy with Rituximab, Gemcitabine and Oxaliplatin - Indolent Lymphoma | Phase 1 / Phase 2 | Terminated | German Low Grade Lymphoma Study Group | 56 | 2003-01-01 | 2015-08-19 |
Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Follicular (7) · Waldenstrom Macroglobulinemia (6) · Lymphoma, Mantle-Cell (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma (2) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hepatitis C (1) · Hodgkin Disease (1) · Lung Neoplasms (1)
Neoplasms (11) · Neoplasms by Histologic Type (11) · Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Lymphoma (8) · Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hematologic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Lymphoma, Non-Hodgkin (7) · Neoplasms, Plasma Cell (7)
Rituximab (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Bortezomib (1) · Cladribine (1) · Diet, Vegan (1) · Gemcitabine (1) · LFB-R603 (1) · Lisaftoclax (1) · Nivolumab (1) · Oxaliplatin (1) · Prednisone (1) · Radiotherapy (1) · Therapeutics (1) · copanlisib (1) · idelalisib (1)
Tel-Aviv Sourasky Medical Center (2) · Chinese Academy of Medical Sciences (1) · German Low Grade Lymphoma Study Group (1) · Henan Cancer Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · National Taiwan University Hospital (1) · Nkarta, Inc. (1) · Qilu Puget Sound Biotherapeutics (dba Sound Biologics) (1) · S*BIO (1) · Shayna Sarosiek, MD (1) · Sutro Biopharma, Inc. (1) · TG Therapeutics, Inc. (1) · The First Affiliated Hospital of Soochow University (1) · University of Arizona (1) · University of Maryland, Baltimore (1)
United States (9) · China (4) · Australia (2) · Israel (2) · Canada (1) · Germany (1)
Anas Younes, MD (1) · Arturo Molina, MD (1) · Daniel O. Persky, MD (1) · David Shook, MD (1) · Einat Even-Sapir, MD, PhD (1) · Jean Yared, MD (1) · Jonathan Friedberg, MD (1) · Julie Vose, MD (1) · Lindsey E. Roeker, MD (1) · Martin Hoffmann, Dr. (1) · Peter Martin, MD (1) · Richard Klasa, MD (1) · Shayna Sarosiek, MD (1) · Sung-Hsin Kuo, M.D.,Ph.D. (1) · Yasmin H Karimi, MD (1)
PMID 25439689, PMID 26248505, PMID 26913560, PMID 27879257, PMID 28945884, PMID 29056470, PMID 30184451, PMID 30811293, PMID 31792945, PMID 33407745, PMID 35538512, PMID 35947804, PMID 36810799, PMID 38179936, PMID 38459156, PMID 40324445, PMID 42216090
P30CA023074 (1)